About this trial
Intrauterine device (IUD) insertion is a common contraceptive procedure often associated with moderate to severe pain, particularly among nulliparous individuals. Current pain management strategies, such as over-the-counter analgesics, are frequently inadequate. Methoxyflurane, a short-acting, self-administered inhaled analgesic, has been shown to provide rapid and effective pain relief in acute and procedural settings. This study aims to evaluate whether 3 mL of inhaled Methoxyflurane (via Penthrox inhaler) improves patient satisfaction by reducing pain and anxiety during IUD insertion.
Eligibility criteria
Qualifiers
Patients with a uterus.
Ages 18 to 55 years.
Undergoing any intrauterine device (IUD) insertion.
English-speaking participants.
Disqualifiers
Inability to provide informed consent.
Confirmed pregnancy.
Use of pain medication other than NSAIDs or acetaminophen (e.g., opioids, benzodiazepines, muscle relaxants) within 24 hours prior to the intervention.
Use of cannabis within 24 hours prior to the intervention.
Trial design
Treatments tested in this trial
- Methoxyflurane
- Saline